Showing 1 to 15 of 748 entries
BUY
It has always been part of their health care portfolio. It is losing some lustre and interest created by Covid but is still a good health care company with a good dividend. He likes others as well, maybe a bit better.
biotechnology / pharmaceutical
HOLD
When you're looking at pharma companies, you want to see the breadth of drugs that are in the pipeline, and any blockbuster drugs in there. You're also looking for dividends. Yield is 3.4%.
biotechnology / pharmaceutical
BUY
PFE vs. JNJ Coin flip. Both are stable for the long run. PFE is slightly cheaper right now.
biotechnology / pharmaceutical
SELL
Always a wall of worry around drug pricing, but rarely does it have a large impact. He sold this name after record revenues from vaccine news. He likes AZN, which is getting approval after approval. Another one is LLY, focusing on its diabetes and weight loss drug.
biotechnology / pharmaceutical
BUY
Healthcare is his biggest sector. HC is seeing the classic shift to defensives as inflation peaks. Also, HC trades at only 18x while utilities and staples trade at 21x, so it's the cheapest defensive. He owns Pfizer, UNH and Regeneron.
biotechnology / pharmaceutical
DON'T BUY
The entire drug sector hasn't been investable since the 1990s, because governments control drug prices and patent expiries. Pfizer is struggling to replace drugs coming off patent, like their cholesterol drug. It's really tough. It's a defensive sector, so the drug companies will hold up better and offer dividend growth.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 19/22, Down 3.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE has triggered its stop at $48. To remain disciplined we recommend covering the position at this time.
biotechnology / pharmaceutical
DON'T BUY
Results highly influenced by Covid vaccine. Earnings might be stagnant going forward. His choice is MRK, reasonable and sustainable multiple of 12x and very good dividend. MRK's major drug is patent-protected until at least 2026, plus great drugs in pipeline.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 19/22, Up 9.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend trailing up the stop (from $42) to $48.
biotechnology / pharmaceutical
BUY
Diversified business, gold standard. PFE is making acquisitions, building out the pipeline from Covid cashflow wins. Good mRNA franchise, benefits of diversity, plus management team executing on pipeline of acquisitions.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick May 28/20, Up 45%) A defensive. Back then, they were working on the vaccine and luckily theirs was the most effective. He trimmed at $55, but still likes and holds it. The company has in the past struggled to build a pipeline of drugs. This morning they announced they will buy a company that treats migraines. They're spending $11 billion on their pipeline, which is promising. They earned $25 billion revenues in vaccines in 2021. Pays a great dividend. Remains a core holding.
biotechnology / pharmaceutical
COMMENT
They report Tuesday. They've made a lot of money during the pandemic. He hopes they buy another drug company to make up for looming patent explorations in the coming years. Shares were crushed today. Good yield and trades at 6x earnings, though.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly PFE has a long pipeline of new drugs focusing on oncology, rare diseases and vaccines, generating over $50 billion in annual sales. It trades at 13x earnings compared to peers at 20x. Latest reported earnings beat expectations by 27% and supports a ROE over 34%. Its dividend is backed by a payout ratio under 40% of cashflow. It is managing its cash reserves conservatively, maintaining a good war chest, while still retiring debt. We would recommend a stop loss at $42.00, looking to achieve $60.50 -- upside potential of 19%. Yield 3.0% (Analysts’ price target is $60.47)
biotechnology / pharmaceutical
DON'T BUY
Has done extremely well with Covid solutions. Not inexpensive for its growth rate. A concern for the stock, though not for humanity, is this opportunity will exhaust itself. Not a bad name if Covid will be a chronic situation. All pharma races the patent clock. He'd prefer MRK.
biotechnology / pharmaceutical
HOLD
Value and price momentum score well. High ROE, 13x price to earnings. Healthy yield of 3%, very reasonable payout ratio. You can own it through the cycles.
biotechnology / pharmaceutical
Showing 1 to 15 of 748 entries

Pfizer Inc(PFE-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 12

Neutral - Hold Signals / Votes : 5

Bearish - Sell Signals / Votes : 7

Total Signals / Votes : 24

Stockchase rating for Pfizer Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Pfizer Inc(PFE-N) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N

Is Pfizer Inc a buy or a sell?

In the last year, 24 stock analysts published opinions about PFE-N. 12 analysts recommended to BUY the stock. 7 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

24 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2022-10-04, Pfizer Inc (PFE-N) stock closed at a price of $44.46.